{Reference Type}: Journal Article
{Title}: Therapeutic Enoxaparin Dosing in Obesity.
{Author}: Appay M;Kharadi S;Nanayakkara S;Ryu JS;Pasalic L;Alffenaar JW;
{Journal}: Ann Pharmacother
{Volume}: 0
{Issue}: 0
{Year}: 2024 Jun 19
{Factor}: 3.463
{DOI}: 10.1177/10600280241256351
{Abstract}: <B>UNASSIGNED: </B>This review aims to systematically summarize the available data on efficacy and safety of therapeutic enoxaparin in obese patients and to identify gaps to guide future research.<BR><B>UNASSIGNED: </B>Medline and Embase were systematically searched for eligible studies (last searched December 20, 2023). Studies were included if they reported on therapeutic dosing regimens, adverse bleeding, thrombotic outcomes, or antifactor Xa (AFXa) monitoring in obese adult patients.<BR><B>UNASSIGNED: </B>The systematic review management tool Covidence was used to manage the study selection and data extraction process. The reference list from eligible studies was screened to determine any additional eligible studies.<BR><B>UNASSIGNED: </B>Sixteen studies were included in the analysis. Studies used a variety of doses, indications, and study designs making comparison difficult. Twelve studies reported the incidence of thrombotic events (median = 1.3% [interquartile range [IQR] = 0.3%-2.3%]) and all studies reported the incidence of bleeding events (median = 5.7% [IQR = 2.4%-14.5%]). Two of the 8 studies analyzing the influence of weight/body mass index (BMI) or dose per kg on AFXa levels reported statistically significant results. One study concluded that BMI did not affect achievement of target AFXa levels. However, the second study found that dosing using actual body weight was an independent predictor of supratherapeutic AFXa levels in the obese population.<BR><B>UNASSIGNED: </B>This is the first comprehensive review with a focus on therapeutic dosing of enoxaparin in obesity and has been conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 statement. Seven of the included studies were published since 2018 indicating that new evidence on this topic is emerging.<BR><B>UNASSIGNED: </B>There was inadequate evidence to support an optimal dosing strategy in obese patients due to the heterogeneity of the studies. The AFXa monitoring may be appropriate to guide dosing in this population. Further research is required to determine a suitable dosing regimen.